• In April 2024, Teva Pharmaceutical Industries Ltd. partnered with Launch Therapeutics, Inc. to develop TEV-248, an innovative inhaled therapy. This combination of a corticosteroid and SABA targets fast relief and inflammation control in asthma. The collaboration merges Teva’s respiratory expertise with Launch Therapeutics’ late-stage drug development capabilities.

• In July 2023, Hormosan Pharma GmbH, a subsidiary of Lupin, introduced Luforbec, a pressurized metered-dose inhaler tailored for the treatment of asthma and COPD in adults. This new therapy combines an inhaled corticosteroid with a long-acting beta2-agonist, offering a dual-action approach to managing chronic respiratory conditions. Designed to deliver effective symptom control and long-term disease management, Luforbec enhances therapeutic options for patients requiring consistent inhalation therapy. The launch represents Lupin’s strategic effort to expand its respiratory portfolio in regulated markets. This innovation underscores the rising demand for combination inhalers that ensure both convenience and efficacy.

In this report, the Inhaled Corticosteroid Device Market has been segmented by Types, Indication, Applications, End-Users, and Geography.

Inhaled Corticosteroid Device Market, Segmentation by Types

The Inhaled Corticosteroid Device Market has been segmented by Types into Beclomethasone Dipropionate, Budesonide, Fluticasone Inhaler Powder, and Mometasone.

Beclomethasone Dipropionate
Beclomethasone Dipropionate continues to be a front-runner in the inhaled corticosteroid (ICS) device market, contributing to nearly 28% of global usage. Widely utilized in the treatment of asthma and COPD, this compound is especially favored for its affordability and proven therapeutic efficacy. Its presence is predominantly seen in pressurized metered-dose inhalers (pMDIs), which are particularly common in emerging economies due to their low production costs and ease of access.

Budesonide
Budesonide-based devices account for about 25% of the total market. Known for its fast-acting anti-inflammatory response and low risk of systemic side effects, Budesonide is a go-to option for long-term respiratory therapy. Available in both dry powder inhalers (DPIs) and nebulized forms, it effectively caters to a diverse patient base, including children and elderly individuals who may require gentler treatment forms.

Fluticasone Inhaler Powder
The Fluticasone Inhaler Powder segment dominates the market with an approximate 30% share, making it the most widely used ICS type globally. It is highly regarded for its potent anti-inflammatory action, user-friendly dosing schedule, and effectiveness in combination inhaler therapies. These features make it a preferred choice in developed healthcare markets, where patient adherence and clinical performance are key decision drivers.

Mometasone
Although Mometasone holds a smaller share at 17%, it is rapidly gaining popularity for its once-daily dosing and mild side effect profile. The compound’s increased acceptance in North America and European regions highlights a growing shift toward next-generation corticosteroids that prioritize both efficacy and patient convenience. As research advances, Mometasone is poised to become a strong competitor in the ICS landscape.

Inhaled Corticosteroid Device Market, Segmentation by Indication

The Inhaled Corticosteroid Device Market has been segmented by Indication into Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others.

Asthma
The asthma segment leads the inhaled corticosteroid (ICS) device market, capturing around 63% of the market share. Inhaled corticosteroids remain a vital component in asthma control, effectively reducing inflammation and minimizing the risk of acute asthma attacks. Their widespread acceptance across different severity levels of asthma contributes to strong global demand. Additionally, improved healthcare access and rising patient awareness are fueling the use of ICS devices in both developed and emerging regions.

Chronic Obstructive Pulmonary Disease (COPD)
The COPD segment accounts for approximately 31% of the ICS device market. These devices play a critical role in managing chronic inflammation and reducing the frequency of exacerbations in COPD patients. ICS treatments are commonly paired with long-acting bronchodilators, particularly for individuals with frequent flare-ups. The increase in global aging populations and higher prevalence of smoking-related respiratory issues are driving the growth of this segment.

Others
Comprising around 6% of the market, the "Others" segment includes treatments for non-asthmatic eosinophilic bronchitis, allergic rhinitis, and other off-label applications of ICS. While relatively small, this segment has emerging potential thanks to advances in clinical research and expanded therapeutic applications. Increased physician comfort with prescribing ICS for niche conditions could stimulate gradual growth in this area.

Inhaled Corticosteroid Device Market, Segmentation by End-Users

The Inhaled Corticosteroid Device Market has been segmented by End-Users into Hospitals, Clinics, and Respiratory Care Center.

Hospitals
The hospital leads the inhaled corticosteroid (ICS) device market in terms of end-user distribution, holding a commanding 48% share. Hospitals are key centers for managing acute respiratory episodes and for initiating treatment in asthma and COPD patients. The presence of expert healthcare staff, advanced facilities, and comprehensive patient management systems supports higher adoption of ICS devices. Furthermore, hospitals often set the tone for long-term treatment adherence, especially when devices are prescribed upon discharge or during routine inpatient care.

Clinics
Accounting for roughly 33% of the market, clinics are becoming increasingly important in the ICS device ecosystem. With easier access and faster service delivery, clinics are a go-to option for patients experiencing early or less severe respiratory symptoms. Their growing role in preventive care and chronic disease management makes them a vital point of ICS distribution. The shift towards ambulatory care models continues to boost this segment, especially in regions emphasizing cost-effective healthcare.

Respiratory Care Centers
The respiratory care centers segment, though smaller at around 19%, plays a crucial role in the long-term management of chronic lung diseases. These centers offer specialized services, including therapy customization, inhaler technique training, and routine follow-up, making them valuable for high-risk patients. As public and private investment in specialized healthcare grows, respiratory care centers are poised to gain a stronger foothold in the ICS market.

Inhaled Corticosteroid Device Market, Segmentation by Geography

In this report, the Inhaled Corticosteroid Device Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Inhaled Corticosteroid Device Market Share (%), by Geographical Region, 2024

North America
North America remains the frontrunner in the inhaled corticosteroid (ICS) device market, commanding nearly 37% of the total share. The region is supported by a robust healthcare infrastructure, high awareness of respiratory diseases, and favorable reimbursement frameworks. With established pharmaceutical giants and a well-informed patient base, the adoption of ICS therapies is consistently high in countries like the U.S. and Canada.

Europe
Holding a significant 28% share, Europe is a mature market for inhaled corticosteroid devices. Widespread adoption of standardized treatment guidelines for asthma and COPD, combined with government-led initiatives promoting preventive care, drive the segment. Technological advancements and the region’s aging demographic further reinforce demand for ICS-based inhalation treatments, particularly in countries such as Germany, France, and the UK.

Asia Pacific
The Asia Pacific market, accounting for around 22%, is witnessing substantial growth driven by rising urbanization, pollution levels, and improved healthcare accessibility. Increased diagnosis of chronic respiratory conditions in countries like India, China, and Japan has led to higher adoption of ICS devices. With healthcare reforms and awareness programs gaining traction, the region is expected to show the fastest growth between 2021 and 2031.

Middle East, Africa, and Latin America
Representing a combined 13% of the global market, the Middle East, Africa, and Latin America regions face barriers such as economic limitations and limited access to respiratory care. Despite this, the market is expanding gradually due to improving infrastructure and international health partnerships. As awareness grows and affordability increases, the use of ICS therapies is expected to rise moderately across these emerging markets.

This report provides an in depth analysis of various factors that impact the dynamics of Inhaled Corticosteroid Device Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers

• Increasing Demand for Asthma and COPD Management
• Technological Advancements in Inhalation Devices
• Growing Awareness About Inhaled Corticosteroid Therapy

• Emphasis on Preventive Healthcare Strategies - The rising global shift toward preventive healthcare is a key factor driving demand in the Inhaled Corticosteroid Device Market. With chronic respiratory diseases like asthma and COPD on the rise, healthcare systems are emphasizing long-term disease control to reduce acute flare-ups and costly hospital visits. Inhaled corticosteroids serve as a cornerstone in prevention-focused treatment plans by minimizing airway inflammation and preventing symptom escalation.

  Growing awareness of the effectiveness of maintenance inhalation therapy is accelerating the use of ICS delivery devices. These devices support early-stage intervention, enhance patient adherence, and help reduce the overall burden of chronic illness. As healthcare models increasingly favor proactive care over reactive treatment, the market for inhaled corticosteroid devices is positioned for sustained growth.

Restraints

• Safety Concerns Related to Corticosteroid Use
• Competition from Alternative Treatment Options
• Limited Reimbursement Coverage

• High Development Costs and Manufacturing Complexity - The high cost of development and the technical challenges of manufacturing inhaled corticosteroid devices remain key restraints for the market. Designing efficient delivery systems involves complex formulation techniques, device engineering, and rigorous safety evaluations to ensure consistent drug performance and targeted lung deposition. These processes lead to substantial research and development expenses and longer timeframes for market entry.

  On the production side, the need for sterile conditions, high-precision components, and continuous quality monitoring increases operational costs and logistical demands. Such complexity limits accessibility for smaller manufacturers and can result in higher product pricing, which affects affordability and widespread adoption, especially in low- and middle-income regions. These factors continue to challenge the scalability and global reach of advanced corticosteroid inhalation devices.

Opportunities

• Development of Novel Corticosteroid Formulations
• Targeted Drug Delivery Systems for Respiratory Conditions
• Strategic Partnerships and Collaborations

• Focus on Personalized Medicine and Precision Inhalation Therapy - The increasing integration of personalized medicine into respiratory care is creating strong growth potential for the Inhaled Corticosteroid Device Market. By tailoring corticosteroid delivery to individual patient characteristics such as disease progression, lung capacity, and treatment response, healthcare providers can achieve better clinical outcomes with fewer side effects. This patient-centric approach is reshaping how chronic conditions like asthma and COPD are managed.

  The emergence of smart inhaler technologies is further enabling precision therapy by offering real-time tracking of inhalation patterns, dosage adherence, and device usage. These digital tools provide valuable insights that help physicians adjust treatment plans in a data-informed manner. As a result, patients benefit from more accurate dosing, reduced exacerbations, and improved disease control.

  Precision inhalation therapy also plays a key role in minimizing systemic exposure, making it especially beneficial for pediatric, geriatric, and high-risk populations. Advances in device engineering such as optimized particle size and controlled flow mechanisms are supporting more targeted and effective drug delivery to the lungs, enhancing both safety and efficacy.

  With the healthcare industry moving toward more tailored and efficient treatment models, the fusion of inhaled corticosteroid devices with personalized care technologies is expected to drive innovation and long-term market expansion. Companies that focus on adaptive, data-supported inhalation systems are likely to gain a competitive edge in this evolving landscape.

Key players in Inhaled Corticosteroid Device Market include :

• Merck and Co
• Pfizer
• Sandoz
• Cipla
• Roche
• Sun Pharmaceutical Industries
• AbbVie
• Boehringer Ingelheim
• Teva Pharmaceutical Industries
• Novartis
• Mylan
• Hikma Pharmaceuticals
• Lupin Pharmaceuticals
• AstraZeneca
• GlaxoSmithKline

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Market Share Analysis
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis